Anticonvulsants and anxiolytics: Barbiturates

Anticonvulsants and anxiolytics: Barbiturates

anatomy

anatomy

Bones and joints of the thoracic wall
Muscles of the thoracic wall
Vessels and nerves of the thoracic wall
Anatomy of the breast
Anatomy of the pleura
Anatomy of the lungs and tracheobronchial tree
Anatomy of the heart
Anatomy of the coronary circulation
Anatomy of the superior mediastinum
Anatomy of the inferior mediastinum
Anatomy clinical correlates: Thoracic wall
Anatomy clinical correlates: Breast
Anatomy clinical correlates: Pleura and lungs
Anatomy clinical correlates: Heart
Anatomy clinical correlates: Mediastinum
Anatomy of the anterolateral abdominal wall
Anatomy of the abdominal viscera: Blood supply of the foregut, midgut and hindgut
Anatomy of the abdominal viscera: Esophagus and stomach
Anatomy of the abdominal viscera: Small intestine
Anatomy of the abdominal viscera: Large intestine
Anatomy of the abdominal viscera: Pancreas and spleen
Anatomy clinical correlates: Anterior and posterior abdominal wall
Anatomy of the pelvic girdle
Anatomy of the pelvic cavity
Bones of the vertebral column
Bones of the lower limb
Fascia, vessels and nerves of the upper limb
Anatomy of the anterior and medial thigh
Muscles of the gluteal region and posterior thigh
Vessels and nerves of the gluteal region and posterior thigh
Anatomy of the popliteal fossa
Anatomy of the leg
Anatomy of the foot
Anatomy of the hip joint
Anatomy of the knee joint
Anatomy of the tibiofibular joints
Joints of the ankle and foot
Bones of the upper limb
Anatomy of the brachial plexus
Anatomy of the pectoral and scapular regions
Anatomy of the arm
Muscles of the forearm
Vessels and nerves of the forearm
Muscles of the hand
Anatomy of the sternoclavicular and acromioclavicular joints
Anatomy of the glenohumeral joint
Anatomy of the elbow joint
Anatomy of the radioulnar joints
Joints of the wrist and hand
Anatomy clinical correlates: Clavicle and shoulder
Anatomy clinical correlates: Axilla
Anatomy clinical correlates: Arm, elbow and forearm
Anatomy clinical correlates: Wrist and hand
Anatomy clinical correlates: Median, ulnar and radial nerves
Major depressive disorder
Suicide
Bipolar and related disorders
Major depressive disorder with seasonal pattern
Premenstrual dysphoric disorder
Generalized anxiety disorder
Social anxiety disorder
Panic disorder
Agoraphobia
Phobias
Obsessive-compulsive disorder
Body focused repetitive disorders
Post-traumatic stress disorder
Schizophrenia
Anorexia nervosa
Bulimia nervosa
Cluster A personality disorders
Cluster B personality disorders
Cluster C personality disorders
Somatic symptom disorder
Factitious disorder
Tobacco use disorder
Opioid use disorder
Cannabis use disorder
Cocaine use disorder
Alcohol use disorder
Bruxism
Insomnia
Narcolepsy (NORD)
Erectile dysfunction
Attention deficit hyperactivity disorder
Disruptive, impulse control, and conduct disorders
Learning disability
Fetal alcohol syndrome
Tourette syndrome
Autism spectrum disorder
Rett syndrome
Mood disorders: Pathology review
Amnesia, dissociative disorders and delirium: Pathology review
Personality disorders: Pathology review
Eating disorders: Pathology review
Psychological sleep disorders: Pathology review
Psychiatric emergencies: Pathology review
Drug misuse, intoxication and withdrawal: Hallucinogens: Pathology review
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Monoamine oxidase inhibitors
Atypical antidepressants
Lithium
Nonbenzodiazepine anticonvulsants
Atypical antipsychotics
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Psychomotor stimulants
Glycolysis
Citric acid cycle
Electron transport chain and oxidative phosphorylation
Gluconeogenesis
Glycogen metabolism
Pentose phosphate pathway
Physiological changes during exercise
Amino acid metabolism
Nitrogen and urea cycle
Fatty acid synthesis
Fatty acid oxidation
Ketone body metabolism
Cholesterol metabolism
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Lactose intolerance
Glycogen storage disease type I
Glycogen storage disease type II (NORD)
Leukodystrophy
Metachromatic leukodystrophy (NORD)
Gaucher disease (NORD)
Niemann-Pick disease types A and B (NORD)
Niemann-Pick disease type C
Fabry disease (NORD)
Tay-Sachs disease (NORD)
Mucopolysaccharide storage disease type 1 (Hurler syndrome) (NORD)
Mucopolysaccharide storage disease type 2 (Hunter syndrome) (NORD)
Cystinosis
Phenylketonuria (NORD)
Cystinuria (NORD)
Homocystinuria
Maple syrup urine disease
Familial hypercholesterolemia
Hypertriglyceridemia
Disorders of carbohydrate metabolism: Pathology review
Disorders of fatty acid metabolism: Pathology review
Dyslipidemias: Pathology review
Glycogen storage disorders: Pathology review
Lysosomal storage disorders: Pathology review
Carbohydrates and sugars
Fats and lipids
Proteins
Folate (Vitamin B9) deficiency
Vitamin B12 deficiency
Wernicke-Korsakoff syndrome
Fat-soluble vitamin deficiency and toxicity: Pathology review
Zinc deficiency and protein-energy malnutrition: Pathology review
Cellular structure and function
Cell membrane
Selective permeability of the cell membrane
Extracellular matrix
Cell-cell junctions
Endocytosis and exocytosis
Osmosis
Resting membrane potential
Nernst equation
Cytoskeleton and intracellular motility
Cell signaling pathways
Adrenoleukodystrophy (NORD)
Zellweger spectrum disorders (NORD)
Alport syndrome
Ehlers-Danlos syndrome
Marfan syndrome
Peroxisomal disorders: Pathology review
Nuclear structure
DNA structure
Transcription of DNA
Translation of mRNA
Amino acids and protein folding
Nucleotide metabolism
DNA replication
Lac operon
DNA damage and repair
Cell cycle
Mitosis and meiosis
DNA mutations
Lesch-Nyhan syndrome
Adenosine deaminase deficiency
Purine and pyrimidine synthesis and metabolism disorders: Pathology review
Polymerase chain reaction (PCR) and reverse-transcriptase PCR (RT-PCR)
Gel electrophoresis and genetic testing
ELISA (Enzyme-linked immunosorbent assay)
Karyotyping
DNA cloning
Fluorescence in situ hybridization

Transcript

Watch video only

Barbiturates are a class of medications that are used as anticonvulsants to manage seizure disorders; to induce anesthesia in surgical procedures; as anxiolytics to relieve anxiety; and to manage insomnia. Barbiturates enhance the effect of gamma-aminobutyric acid, or GABA, which is the major inhibitory neurotransmitter in the brain, by binding to its receptor.

It’s pretty well-established that your brain’s really important. It controls your feelings, your movements, your sleep, your memory… It controls everything, whether you’re aware of it or not. The cells that make up our brain are called neurons. Neurons communicate with each other through neurotransmitters. When one neuron is stimulated, it’ll release excitatory neurotransmitters like glutamate, which bind to receptors on the next neuron. This causes the next neuron to depolarize and release its own excitatory neurotransmitters, propagating the signal throughout the brain.

Now, we also have inhibitory neurons that will shut down this chain of events. These neurons release the main inhibitory neurotransmitter in the nervous system, gamma-aminobutyric acid, or GABA, which binds to GABA receptors on other neurons. These receptors are large multi-unit complexes that form ligand-gated ion channels, which open up to let Cl- ions into the cell. The influx of negatively charged ions causes hyperpolarization, where the cell’s membrane potential becomes more negative, which means it’s much more difficult for it to depolarize and fire off an action potential, and that means it’s less responsive to stimuli.

Now, there are cases where neurons in the brain start sending out more excitatory signals than normal. This can occur due to either too much excitation by the excitatory neurotransmitters, or too little inhibition by the inhibitory neurotransmitters like GABA. Excessive excitatory signals can cause psychiatric disorders like anxiety, and neurological disorders like seizures and epilepsy.

Okay, so one way we can decrease the excitatory signals is by enhancing the effect of inhibitory neurons through medication like barbiturates. Common medications in this class include amobarbital, butabarbital, methohexital, PENTobarbital, PHENobarbital, and primidone, which is a prodrug of PHENobarbital. Another medication from this group is thiopental, but it’s not available in the U.S. and Canada anymore. These medications target the GABAA receptors but they bind at a different site than GABA or benzodiazepines. At lower doses, barbiturates enhance the effect of GABA by increasing the duration of Cl- channels opening, thereby increasing the influx of Cl- ions. As a result, high intracellular concentrations of Cl- ions cause membrane hyperpolarization, which means it’s much more difficult for the neuron to depolarize and fire off an action potential. This differentiates them from benzodiazepines which also work by binding to GABAA receptors, but in contrast to barbiturates, they work by increasing the frequency of Cl- channels opening. So remember, barbiDurates increase duration! At higher doses, these medications can mimic GABA effect by triggering the opening of these channels even without GABA. In addition, barbiturates block excitatory glutamate receptors called AMPA receptors and decrease neuronal excitability; but they also inhibit voltage-gated calcium channels and decrease the release of glutamate.

Now, let’s draw a chart of the dose-dependent effects of barbiturates. On the left side of the chart, let’s place central nervous effects; and on the bottom let’s place dose. Low doses of barbiturates cause sedation, disinhibition, and anxiolysis; but as the dose increases, barbiturates cause hypnosis, anesthesia, medullary depression, and eventually coma

Now at a higher dose, barbiturates also inhibit the electron transport chain, which is a process that occurs within the inner mitochondrial membrane and results in the synthesis of adenosine triphosphate, or ATP. ATP is the main form of energy that keeps all of our body cells going. So when the electron transport chain gets interrupted, the ATP synthesis doesn’t happen and that can eventually lead to the death of the cell. Barbiturates also induce a class of enzymes called cytochrome P450. These enzymes are involved in the metabolism of various medications like benzodiazepines, phenytoin, quinidine, warfarin, and others. Increased cytochrome P450 activity can cause these medications to break down more rapidly, so larger doses may be needed to achieve a therapeutic effect.  

Alright, now barbiturates are indicated when the neurons get “super excited” and we want to calm them down, like during an epileptic seizure where clusters of neurons in the brain become temporarily impaired and start firing off a ton of excitatory signals. Moreover, PHENobarbital is the first-line treatment for neonatal convulsions. Also, this feature makes them useful for treating acute anxiety states like a panic attack. In addition, barbiturates can be used for preoperative sedation and to induce anesthesia; but they can also be given as a hypnotic to induce sleep since we basically want to depress the function of the person’s nervous system. Finally, in life-threatening conditions, such as increased intracranial pressure, these medications can be used to decrease cerebral blood flow and induce coma, which is also known as the barbiturate-induced coma.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Does bright light have an anxiolytic effect? - an open trial" BMC Psychiatry (2007)
  5. "The use of phenobarbital and other anti-seizure drugs in newborns" Seminars in Fetal and Neonatal Medicine (2017)
  6. "Pediatric Epilepsy" Demos Medical Pub (2001)
  7. "Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, diphenylhydantoin, ethotoin, metharbital, and methylphenylethylhydantoin in motor seizures" Clinical Pharmacology & Therapeutics (1962)